共 50 条
Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction COMPLETE Trial
被引:86
|作者:
Wood, David A.
[1
]
Cairns, John A.
[1
]
Wang, Jia
[2
,3
]
Mehran, Roxana
[4
]
Storey, Robert F.
[5
]
Nguyen, Helen
[2
,3
]
Meeks, Brandi
[2
,3
]
Kunadian, Vijay
[6
,7
]
Tanguay, Jean-Francois
[8
,9
]
Kim, Hahn-Ho
[10
]
Cheema, Asim
[11
]
Deghani, Payam
[12
]
Natarajan, Madhu K.
[2
,3
]
Jolly, Sanjit S.
[2
,3
]
Amerena, John
[13
]
Keltai, Matyas
[14
]
James, Stefan
[15
,16
]
Hlinomaz, Ota
[17
]
Niemela, Kari
[18
]
AlHabib, Khalid
[19
]
Lewis, Basil S.
[20
]
Nguyen, Michel
[21
]
Sarma, Jaydeep
[22
]
Dzavik, Vladimir
[23
]
Della Siega, Anthony
[24
]
Mehta, Shamir R.
[2
,3
]
机构:
[1] Univ British Columbia, St Pauls & Vancouver Gen Hosp, Ctr Cardiovasc Innovat, 2775 Laurel St 9th Floor, Vancouver, BC V5Z 1M9, Canada
[2] McMaster Univ, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada
[3] Hamilton Hlth Sci, 237 Barton St East, Hamilton, ON L8L 2X2, Canada
[4] Zena A Wiener Cardiovasc Inst, Icahn Sch Med Mt Sinai, New York, NY USA
[5] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England
[6] Newcastle Univ, Inst Cellular Med, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England
[7] Newcastle Tyne Hosp NHS Fdn Trust, Cardiothorac Ctr, Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England
[8] Montreal Heart Inst, Montreal, PQ, Canada
[9] Univ Montreal, Montreal, PQ, Canada
[10] St Marys Gen Hosp, Kitchener, ON, Canada
[11] St Michaels Hosp, Toronto, ON, Canada
[12] Univ Saskatchewan, Prairie Vasc Res Network, Regina, SK, Canada
[13] Kardinia House, Geelong, Vic, Australia
[14] Hungarian Inst Cardiol, Budapest, Hungary
[15] Uppsala Clin Res Ctr, Uppsala, Sweden
[16] Dept Med Sci, Uppsala, Sweden
[17] Univ Hosp St Anne, Brno, Czech Republic
[18] Tampere Univ Hosp, Heart Ctr, Tampere, Finland
[19] King Fahad Cardiac Ctr, Dept Cardiac Serv, Jeddah, Saudi Arabia
[20] Lady Davis Carmel Med Ctr, Cardiovasc Clin Res Inst, Haifa, Israel
[21] Univ Sherbrooke, Ctr Hosp, Div Cardiol, Quebec City, PQ, Canada
[22] Wythenshawe Hosp, North West Heart Ctr, Manchester, Lancs, England
[23] Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada
[24] Victoria Heart Inst Fdn, Dept Cardiac Serv, Victoria, BC, Canada
基金:
加拿大健康研究院;
关键词:
complete revascularization;
percutaneous coronary intervention;
RANDOMIZED-TRIAL;
STRATEGIES;
GUIDELINES;
MANAGEMENT;
LESION;
D O I:
10.1016/j.jacc.2019.09.051
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
BACKGROUND The COMPLETE (Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI) trial demonstrated that staged nonculprit lesion percutaneous coronary intervention (PCI) reduced major cardiovascular (CV) events in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (CAD). OBJECTIVES The purpose of this study was to determine the effect of nonculprit-lesion PCI timing on major CV outcomes and also the time course of the benefit of complete revascularization. METHODS Following culprit-lesion PCI, 4,041 patients with STEMI and multivessel CAD were randomized to staged nonculprit-lesion PCI or culprit-lesion only PCI. Randomization was stratified according to investigator-planned timing of nonculprit-lesion PCI: during or after the index hospitalization. The first coprimary outcome was the composite of CV death or myocardial infarction (MI). In pre-specified analyses, hazard ratios (HRs) were calculated for each time stratum. Landmark analyses of the entire population were performed within 45 days and after 45 days. RESULTS For nonculprit-lesion PCI planned during the index hospitalization (actual time: median 1 day), CV death or MI was reduced with complete revascularization compared with culprit-lesion only PCI (HR: 0.77; 95% confidence interval [CI]: 0.59 to 1.00). For nonculprit lesion PCI planned to occur after hospital discharge (actual time: median 23 days), CV death or MI was also reduced with complete revascularization (HR: 0.69; 95% CI: 0.49 to 0.97; interaction p = 0.62). Landmark analyses demonstrated an HR of 0.86 (95% CI: 0.59 to 1.24) during the first 45 days and 0.69 (95% CI: 0.54 to 0.89) from 45 days to the end of follow-up for intended nonculprit lesion PCI versus culprit lesion only PCI. CONCLUSIONS Among STEMI patients with multivessel disease, the benefit of complete revascularization over culprit-lesion only PCI was consistent irrespective of the investigator-determined timing of nonculprit-lesion intervention. The benefit of complete revascularization on hard clinical outcomes emerged mainly over the long term. (C) 2019 by the American College of Cardiology Foundation.
引用
收藏
页码:2713 / 2723
页数:11
相关论文